Media headlines about KemPharm (NASDAQ:KMPH) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KemPharm earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 46.3014532564516 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

KemPharm (NASDAQ:KMPH) traded up 1.89% during trading on Friday, reaching $2.70. The company had a trading volume of 7,009 shares. The company’s market capitalization is $39.57 million. The company has a 50 day moving average price of $3.24 and a 200 day moving average price of $3.86. KemPharm has a 52-week low of $2.45 and a 52-week high of $5.40.

KemPharm (NASDAQ:KMPH) last posted its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.19. On average, equities analysts forecast that KemPharm will post ($2.72) EPS for the current fiscal year.

A number of research firms recently commented on KMPH. Oppenheimer Holdings, Inc. set a $13.00 price objective on KemPharm and gave the stock a “buy” rating in a report on Thursday, August 10th. Canaccord Genuity set a $7.00 price objective on KemPharm and gave the stock a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. ValuEngine downgraded KemPharm from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Finally, Roth Capital began coverage on KemPharm in a report on Wednesday, June 28th. They issued a “buy” rating and a $8.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $8.10.

COPYRIGHT VIOLATION WARNING: “KemPharm (KMPH) Receives Daily Media Sentiment Score of 0.09” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at

In other KemPharm news, CEO Travis C. Mickle purchased 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The shares were acquired at an average cost of $3.45 per share, for a total transaction of $27,600.00. Following the completion of the acquisition, the chief executive officer now owns 1,629,612 shares of the company’s stock, valued at approximately $5,622,161.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 17,275 shares of company stock worth $51,808 in the last 90 days. Corporate insiders own 22.80% of the company’s stock.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.